Mesa Nilda

SEC source: 0001756697-26-000004 · primarydocument.xml · derivative · entry 4

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,430

Underlying: Common Stock · 130 shares

Expires 2028-10-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001756697-26-000004 · primarydocument.xml · nonDerivative · entry 3

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,580

SEC source: 0001756697-26-000004 · primarydocument.xml · nonDerivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,430

F1 · price: This transaction was executed in multiple trades at prices ranging from $505.76 to $505.985. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001756697-26-000004 · primarydocument.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,560

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001756697-26-000003 · primarydocument.xml · derivative · entry 3

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,190

Underlying: Common Stock · 1,190 shares

Expires 2033-07-22

F2 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

SEC source: 0001756697-26-000003 · primarydocument.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 380

Underlying: Common Stock · 380 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F2 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001756697-26-000002 · primarydocument.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 650 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock.

F1 · kind: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock.

F1 · price: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock.

F2 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001756697-26-000002 · primarydocument.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,678

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock.

F1 · price: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001756697-26-000001 · primarydocument.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,028

SEC source: 0001756697-25-000002 · primarydocument.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,286

SEC source: 0001562180-25-005528 · primarydocument.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 590 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares received upon vesting of restricted stock units on July 25, 2025. Restricted stock units converted on a one-for-one basis into shares of common stock.

F1 · price: Shares received upon vesting of restricted stock units on July 25, 2025. Restricted stock units converted on a one-for-one basis into shares of common stock.

F2 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001562180-25-005528 · primarydocument.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,473

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Shares received upon vesting of restricted stock units on July 25, 2025. Restricted stock units converted on a one-for-one basis into shares of common stock.

F1 · price: Shares received upon vesting of restricted stock units on July 25, 2025. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001562180-25-005528 · primarydocument.xml · derivative · entry 4

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,830

Underlying: Common Stock · 1,830 shares

Expires 2035-07-24

F4 · shares: Annual non-employee director award.

SEC source: 0001562180-25-005528 · primarydocument.xml · derivative · entry 3

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650

Underlying: Common Stock · 650 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · shares: Annual non-employee director award.

F3 · price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F2 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001562180-25-005066 · primarydocument.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,883

F1 · price: This transaction was executed in multiple trades at prices ranging from $289.68 to $290.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-24-008660 · primarydocument.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,528

SEC source: 0001415889-24-026612 · form4-11122024_041123.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,783

SEC source: 0001415889-24-020166 · form4-07262024_040713.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 590

Underlying: Common Stock · 590 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001415889-24-020166 · form4-07262024_040713.xml · derivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,440

Underlying: Common Stock · 1,440 shares

Expires 2034-07-25

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

SEC source: 0001415889-24-019549 · form4-07152024_040708.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 900 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares received upon vesting of restricted stock units on July 13, 2024. Restricted stock units converted on a one-for-one basis into shares of common stock.

F1 · kind: Shares received upon vesting of restricted stock units on July 13, 2024. Restricted stock units converted on a one-for-one basis into shares of common stock.

F2 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001415889-24-019549 · form4-07152024_040708.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,007

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Shares received upon vesting of restricted stock units on July 13, 2024. Restricted stock units converted on a one-for-one basis into shares of common stock.

F1 · price: Shares received upon vesting of restricted stock units on July 13, 2024. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-24-018226 · form4-06262024_040604.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,107

SEC source: 0001415889-24-009443 · form4-03292024_040302.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,373

SEC source: 0001415889-23-016794 · form4-12202023_041201.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,698

SEC source: 0001415889-23-013303 · form4-09152023_040901.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,303

SEC source: 0001415889-23-011151 · form4-07172023_060709.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 900

Underlying: Common Stock · 900 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001415889-23-011151 · form4-07172023_060709.xml · derivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,280

Underlying: Common Stock · 2,280 shares

Expires 2033-07-13

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-23-010950 · form4-07072023_040712.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 880 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares received upon vesting of restricted stock units on July 7, 2023. Restricted stock units converted on a one-for-one basis into shares of common stock.

F1 · kind: Shares received upon vesting of restricted stock units on July 7, 2023. Restricted stock units converted on a one-for-one basis into shares of common stock.

F2 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001415889-23-010950 · form4-07072023_040712.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,686

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Shares received upon vesting of restricted stock units on July 7, 2023. Restricted stock units converted on a one-for-one basis into shares of common stock.

F1 · price: Shares received upon vesting of restricted stock units on July 7, 2023. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-23-007550 · form4-05082023_090518.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,806

SEC source: 0001415889-22-011113 · form4-11072022_041101.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,180

SEC source: 0001415889-22-010045 · form4-09302022_040901.xml · nonDerivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,470

F2 · price: This transaction was executed in multiple trades at prices ranging from $207.19 to $207.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-22-010045 · form4-09302022_040901.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,870

F1 · price: This transaction was executed in multiple trades at prices ranging from $211.01 to $211.125. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-22-007609 · form4-07082022_020734.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,080

Underlying: Common Stock · 1,080 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007609 · form4-07082022_020734.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,720

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-22-007626 · form4a-07112022_040706.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,080 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · shares: This amendment corrects an error in the original filing, which incorrectly listed these restricted stock units as "Acquired" instead of "Disposed of".

F4 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F4 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007626 · form4a-07112022_040706.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,720

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-22-007609 · form4-07082022_020734.xml · derivative · entry 4

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,490

Underlying: Common Stock · 2,490 shares

Expires 2032-07-07

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007609 · form4-07082022_020734.xml · derivative · entry 3

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 880

Underlying: Common Stock · 880 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001127602-21-021764 · form4.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,080

Underlying: Common Stock · 1,080 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · shares: Annual non-employee director grant of restricted stock units, which are awarded each year on the date of the first board meeting following the issuer's Annual Meeting of Shareholders.

F2 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F2 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001127602-21-021764 · form4.xml · derivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,230

Underlying: Common Stock · 3,230 shares

Expires 2031-07-08

F1 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the first board meeting following the issuer's Annual Meeting of Shareholders.

F2 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001127602-21-020807 · form4.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,680 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001127602-21-020807 · form4.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,680

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on June 26, 2021. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001127602-22-005324 · form4a.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,680 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

F4 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

SEC source: 0001127602-22-005324 · form4a.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,640

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This transaction was originally reported on a Form 4 filed on June 29, 2021, which incorrectly reported the amount beneficially owned following reported transaction as 1,680 due to a clerical error.

SEC source: 0001104659-20-078801 · a4.xml · derivative · entry 4

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,160

Underlying: Common Stock · 5,160 shares

Expires not disclosed

F6 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders.

F7 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F8 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001104659-20-078801 · a4.xml · derivative · entry 3

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,680

Underlying: Common Stock · 1,680 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded each year on the date of the issuer's Annual Meeting of Shareholders.

F4 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

F5 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

SEC source: 0001104659-20-078801 · a4.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,300 shares

Expires 2029-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

SEC source: 0001104659-20-078801 · a4.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,960

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on June 26, 2020. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001127602-20-001787 · form4.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,660 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares received upon vesting of restricted stock units on October 31, 2019. Restricted stock units converted on a one-for-one basis into shares of common stock.

F2 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

F2 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.